Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease

Background and study aims: Hepatitis C virus (HCV) prevalence inchronic kidney disease (CKD) patients is significantly higher than in the general population. This study evaluated the efficacy and safety of combined ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with renal impairment.

Patients and methods: Our study included 829 patients with normal kidney functions (group 1) and 829 patients with CKD (group 2),which were subdivided into patients not requiring dialysis (group 2a) and those on hemodialysis (group2b). Patients received regimens of ombitasvir/paritaprevir/ritonavir with or without ribavirin or sofosbuvir/ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks. Clinical and laboratory assessment was done before treatment, and patients were followed up for12 weeks after treatment.

Results: The sustained virological response (SVR) at week 12 was significantly higher in group 1 than in the other three groups/subgroups, being 94.2% vs 90.2%, 90%, and 90.7%, respectively. The regimen with the highest SVR was ombitasvir/paritaprevir/ritonavir with ribavirin. The most common adverse event was anemia, which was more common in group 2.

Conclusion: Ombitasvir/paritaprevir/ritonavir-based therapy in chronic HCV patients with CKD is highly effective, with minimal side effects despite ribavirin-induced anemia.

Comments：

This study aimed to evaluate the effectiveness and safety of combined ombitasvir/paritaprevir/ritonavir-based therapy in patients with chronic hepatitis C virus (HCV) and chronic kidney disease (CKD). The study included 829 patients with normal kidney functions and 829 patients with CKD, who were further subdivided into patients not requiring dialysis and those on hemodialysis. Patients received ombitasvir/paritaprevir/ritonavir-based therapy with or without ribavirin or sofosbuvir/ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks. Clinical and laboratory assessment was done before treatment, and patients were followed up for 12 weeks after treatment.

The results showed that the sustained virological response (SVR) at week 12 was significantly higher in patients with normal kidney function (94.2%) compared to those with CKD (90.2%, 90%, and 90.7% for groups 2a, 2b with ribavirin, and 2b without ribavirin, respectively). The regimen with the highest SVR was ombitasvir/paritaprevir/ritonavir with ribavirin. The most common adverse event was anemia, which was more common in patients with CKD.

In conclusion, ombitasvir/paritaprevir/ritonavir-based therapy is highly effective and safe in patients with chronic HCV and CKD, with minimal side effects despite ribavirin-induced anemia. The results suggest that this therapy can be a viable treatment option for patients with chronic HCV and CKD.

Related Products

Cat.No.	Product Name	Information
S5403	Ombitasvir (ABT-267)	Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.

Related Targets

HCV Protease